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**Abstract**

The multimodal antidepressant vortioxetine is thought to exert its therapeutic effects through 5-HT1A receptor agonism, 5-HT1B receptor partial agonism and 5-HT3, 5-HT1D and 5-HT7 receptor antagonism in addition to inhibition of serotonin (5-HT) reuptake. This presentation will describe the approach that was taken in the vortioxetine clinical development program to assess vortioxetine's potential to treat cognitive dysfunction (CD) in Major Depressive Disorder (MDD), and how this led to the inclusion of vortioxetine's positive effects on aspects of CD in MDD patients in the prescription information to doctors and patients in more than 50 countries worldwide including the European Community. The presentation will review the alignment between preclinical and clinical research with a particular emphasis on cognition, and discuss the value of continued research to elucidate vortioxetine's pharmacological potential even at an advanced stage of clinical development.

The clinical evidence for vortioxetine's beneficial effects on CD in MDD includes the results from 3 large, prospective, placebo-controlled studies in both elderly and adult MDD patients, two of which had CD as the primary endpoint. Vortioxetine over a dose range of 5 to 20 mg was consistently statistically significantly better than placebo on improving CD, as assessed using the Digit Symbol Substitution Test (DSST). DSST was chosen because it is an objective measure that is sensitive to change and to the integrity of multiple cognitive domains relevant for MDD. In the two studies that had an active reference included, duloxetine did not improve DSST performance versus placebo despite improvement in depressive symptoms. Moreover, in all three studies, after adjusting for the effect on depressive symptoms, most of vortioxetine's benefit on cognitive performance was retained, indicating a mood-independent effect on the DSST. This presentation will also include evidence from additional neuropsychological tests, measures of functionality including the UCSD Performance-Based Skills Assessment (UPSA), and from patient-reported cognitive functioning.

Vortioxetine's distinct clinical profile is supported by its pharmacological profile. Preclinical studies of vortioxetine using clinically equivalent doses demonstrated positive effects in several animal models of CD where other antidepressants had no effect. Furthermore, vortioxetine enhanced glutamatergic output from cortical and hippocampal pyramidal cells (key integrators of cognitive processing) through attenuation of the inhibitory control of GABA interneurons. Morphologically this led to a superior effect of vortioxetine on neurogenesis, dendritic branching and maturation of dendritic spines; all measures that further substantiate the mechanistic rationale for vortioxetine's positive effects on cognitive function. Doses corresponding to the high end of the clinical dose range increased extracellular levels of norepinephrine, dopamine, acetylcholine, and histamine in hippocampus and prefrontal cortex. These effects might also contribute to vortioxetine's beneficial effects on cognition. Lastly, recent data from a human imaging study in remitted MDD patients suggested that vortioxetine improves neuronal efficiency during cognitive processes, which provides further mechanistic evidence for its beneficial effect on cognitive function.

Through continued research efforts vortioxetine showed to be an antidepressant with a distinct clinical and pharmacological profile different from other currently available antidepressants, with a proven beneficial effect on CD in patients with MDD.
